Hyperuricemia is associated with immunoglobulin G N-glycosylation: A community-based study of glycan biomarkers

Author Identifier

wei wang


Document Type

Journal Article

Publication Title

OMICS : A Journal of Integrative Biology


Mary Ann Liebert


School of Medical and Health Sciences




National Health and Medical Research Council (NHMRC).

National Natural Science Foundation of China.

National Key R&D Program of China.

European Commission Horizon 2020.

Science and Technology Development Project in Taian.

Grant Number

NHMRC Number : 1112767


Hou, H., Xu, X., Sun, F., Zhang, X., Dong, H., Wang, L., ... Wang, Y. (2019). Hyperuricemia is associated with immunoglobulin G N-glycosylation: A community-based study of glycan biomarkers. Omics: A Journal of Integrative Biology, 23(12), 660-667. Available here


The increasing prevalence of hyperuricemia has been recognized as an emerging public health concern in both developed and developing countries. Hyperuricemia is a metabolic condition characterized by an elevated serum uric acid, and associated with renal damage, diabetes, autoimmune disorders, and cardiovascular diseases. Although human genetic variation has been recognized as a factor, posttranslational cellular processes and glycan biomarkers have not been studied extensively for susceptibility to hyperuricemia. We evaluated whether immunoglobulin (Ig)G N-glycans play a role in hyperuricemia in the general population. This cross-sectional study enrolled 635 participants (208 men and 427 women), ages ≥18 years, from a community-based population in Beijing, China. The IgG N-glycan composition of serum was analyzed by an ultraperformance liquid chromatography method. The prevalence of hyperuricemia observed in this sample was 5.98% (14.9% in men and 1.6% in women). Serum uric acid level was positively correlated with glycan peaks (GP)1, GP2, GP4, GP6, GP10, and GP11, whereas it was negatively correlated with GP12, GP13, GP14, GP15, GP18, and GP20. The combination of GP9, GP10, body mass index, and gender distinguished individuals with hyperuricemia from subjects without hyperuricemia, with an area under the curve value of 0.849 (95% confidence interval: 0.784-0.915). These findings collectively suggest a possible link between hyperuricemia and IgG N-glycans, which might be potentially mediated through inflammation-related mechanisms. Additional research on glycan biomarkers in independent and community-based population samples might allow the development of glycan diagnostics for hyperuricemia and gout in the future.



Access Rights